公开(公告)号：US08343760B2

公开(公告)日：2013-01-01

申请号：US12996196

申请日：2009-06-05

申请人： Wuyuan Lu ,  Davide Zella ,  Min Liu ,  Changqing Li

发明人： Wuyuan Lu ,  Davide Zella ,  Min Liu ,  Changqing Li

IPC分类号： C12N5/00 ,  C12N15/00 ,  C12P21/06 ,  C07H21/04 ,  A61K38/00 ,  A61K38/04

CPC分类号： C07K14/43522

摘要： The present invention relates to novel polypeptides that activate p53, and the polynucleotides encoding these p53 activator peptides. The present invention also relates to pharmaceutical compositions comprising the p53 activator peptides as well as methods of treating abnormal conditions, such as malignant tumors, with the methods comprising administering the pharmaceutical compositions of the present invention to a subject in need of treatment thereof.

摘要翻译： 本发明涉及活化p53的新型多肽，以及编码这些p53活化肽的多核苷酸。 本发明还涉及包含p53激活剂肽的药物组合物以及治疗异常病症如恶性肿瘤的方法，包括将本发明的药物组合物施用于需要治疗的受试者。

公开(公告)号：US20110183917A1

公开(公告)日：2011-07-28

申请号：US12996196

申请日：2009-06-05

申请人： Wuyuan Lu ,  Davide Zella ,  Min Liu ,  Changqing Li

发明人： Wuyuan Lu ,  Davide Zella ,  Min Liu ,  Changqing Li

IPC分类号： A61K38/16 ,  C12N15/63 ,  C12N5/10 ,  C12N1/00 ,  C12P21/02 ,  C07K14/00 ,  C07K7/08 ,  C07H21/00 ,  A61K38/10 ,  A61P35/00

CPC分类号： C07K14/43522

摘要： The present invention relates to novel polypeptides that activate p53, and the polynucleotides encoding these p53 activator peptides. The present invention also relates to pharmaceutical compositions comprising the p53 activator peptides as well as methods of treating abnormal conditions, such as malignant tumors, with the methods comprising administering the pharmaceutical compositions of the present invention to a subject in need of treatment thereof.

摘要翻译： 本发明涉及活化p53的新型多肽，以及编码这些p53活化肽的多核苷酸。 本发明还涉及包含p53激活剂肽的药物组合物以及治疗异常病症如恶性肿瘤的方法，包括将本发明的药物组合物施用于需要治疗的受试者。

公开(公告)号：US07528107B2

公开(公告)日：2009-05-05

申请号：US11565107

申请日：2006-11-30

申请人： Jishu Shi ,  Shelly Aono ,  Wuyuan Lu

发明人： Jishu Shi ,  Shelly Aono ,  Wuyuan Lu

IPC分类号： A01N37/18 ,  A61K38/00

CPC分类号： A61K38/1729

摘要： Human α-defensins are inhibitors of interleukin-1β post transitional processing and release. Interleukin-1β is a key cytokine involved in the initiation and amplification of the inflammatory process, including the inflammation of diseases such as Crohn's Disease and Ulcerative Colitis. Particularly, human neutrophil defensin-1(HNP-1) produced mainly by neutrophils, and human α-defensin 5(HD-5) produced by Paneth cells has been found to block interleukin-1β post transitional processing and release. Thus, a pharmaceutical composition and method for treating inflammation in the mammalian tissues is herein disclosed. The pharmaceutical composition is a therapeutic supplementation of a metabolic pathway to reduce inflammation comprising a human α-defensins in a therapeutically effective amount or an amide, ester or salt thereof and a pharmaceutically effective carrier. The method for treating inflammation in mammalian tissues includes administering a human α-defensins to a mammal in an amount effective to inhibit the post translational processing and release of interleukin-1β.

摘要翻译： 人α-防御素是过渡性处理和释放后白细胞介素-1β的抑制剂。 白介素-1beta是涉及炎性过程的引发和扩增的关键细胞因子，包括诸如克罗恩病和溃疡性结肠炎的疾病的炎症。 特别是主要由嗜中性粒细胞产生的人中性粒细胞防御素-1（HNP-1），Paneth细胞产生的人α-防御素5（HD-5）已经被发现阻断了过渡性加工和释放后的白介素-1beta。 因此，本文公开了用于治疗哺乳动物组织中的炎症的药物组合物和方法。 药物组合物是治疗性补充代谢途径以减少炎症，其包含治疗有效量的人α-防御素或其酰胺，酯或其盐和药学上有效的载体。 用于治疗哺乳动物组织中的炎症的方法包括以有效抑制白细胞介素-1β的翻译后加工和释放的量向哺乳动物施用人α-防御素。

公开(公告)号：US20060172945A1

公开(公告)日：2006-08-03

申请号：US11347538

申请日：2006-02-03

申请人： Wuyuan Lu ,  Fiorenza Cocchi ,  Zhibin Wu

发明人： Wuyuan Lu ,  Fiorenza Cocchi ,  Zhibin Wu

IPC分类号： A61K38/16 ,  A61K31/7076 ,  A61K31/551 ,  A61K31/513 ,  A61K31/522

CPC分类号： A61K38/1709 ,  A61K31/513 ,  A61K31/522 ,  A61K31/551 ,  A61K31/7076 ,  A61K45/06 ,  A61K2300/00

摘要： A method to reduce replication of HIV-1, involving administering a therapeutically effective amount of recombinant HNP4 to a subject in need thereof to combat HIV-1 infection. The HNP4 agent may be utilized in pharmaceutical compositions including a pharmaceutically acceptable carrier and an anti-viral agent, e.g., an anti-viral agent, or combination of such agents, such as nucleoside RT inhibitors, CCR5 inhibitors/antagonists, viral entry inhibitors, and functional analogs thereof.

摘要翻译： 一种减少HIV-1复制的方法，包括向有需要的受试者施用治疗有效量的重组HNP4以对抗HIV-1感染。 HNP4剂可以用于药物组合物，包括药学上可接受的载体和抗病毒剂，例如抗病毒剂，或这些试剂的组合，例如核苷RT抑制剂，CCR5抑制剂/拮抗剂，病毒进入抑制剂， 及其功能类似物。

公开(公告)号：US20090214662A1

公开(公告)日：2009-08-27

申请号：US12162011

申请日：2007-01-24

申请人： Erik P.H. de Leeuw ,  Wuyuan Lu

发明人： Erik P.H. de Leeuw ,  Wuyuan Lu

IPC分类号： A61K9/14

CPC分类号： A61K31/138 ,  A61K9/5052 ,  A61K9/5068 ,  A61K38/164 ,  A61K38/1729 ,  A61K47/32 ,  A61K47/34 ,  Y02A50/475 ,  Y02A50/481

摘要： The invention provides surface-layer protein coated microspheres for delivery of a therapeutic agent to the intestine. These surface-layer protein coated microspheres generally include a core encapsulated by a microsphere which is coated by surface layer protein. The core includes a therapeutic agent, such as a defensin. The invention also includes methods of making and using the surface-layer protein coated microspheres of the invention for administering therapeutic agents to a subject in need thereof. The invention also includes pharmaceutical dosage units that include the surface-layer protein coated microspheres of the invention. The invention further includes various labeled defensins for use in the study of the properties and actions of defensins, and further includes the use of defensins, particularly HD5α in the treatment of inflammatory conditions of the bowel, such as Crohn's disease.

摘要翻译： 本发明提供了用于将治疗剂递送至肠的表面层蛋白质包被的微球。 这些表面层蛋白质包被的微球通常包括由表面蛋白质包被的微球包裹的核心。 核心包括治疗剂，如防御素。 本发明还包括制备和使用本发明的表面层蛋白质包被的微球的方法，用于向有需要的受试者施用治疗剂。 本发明还包括药物剂量单位，其包括本发明的表面层蛋白质包被的微球。 本发明还包括用于研究防御素的性质和作用的各种标记的防御素，并且还包括使用防御素，特别是HD5α在治疗肠道炎症性疾病如克罗恩病中的用途。

公开(公告)号：US20080051333A1

公开(公告)日：2008-02-28

申请号：US11565107

申请日：2006-11-30

申请人： Jishu Shi ,  Shelly Aono ,  Wuyuan Lu

发明人： Jishu Shi ,  Shelly Aono ,  Wuyuan Lu

IPC分类号： A61K38/17

CPC分类号： A61K38/1729

摘要： Human α-defensins are inhibitors of interleukin-1β post transitional processing and release. Interleukin-1β is a key cytokine involved in the initiation and amplification of the inflammatory process, including the inflammation of diseases such as Crohn's Disease and Ulcerative Colitis. Particularly, human neutrophil defensin-1(HNP-1) produced mainly by neutrophils, and human α-defensin 5(HD-5) produced by Paneth cells has been found to block interleukin-1β post transitional processing and release. Thus, a pharmaceutical composition and method for treating inflammation in the mammalian tissues is herein disclosed. The pharmaceutical composition is a therapeutic supplementation of a metabolic pathway to reduce inflammation comprising a human α-defensins in a therapeutically effective amount or an amide, ester or salt thereof and a pharmaceutically effective carrier. The method for treating inflammation in mammalian tissues includes administering a human α-defensins to a mammal in an amount effective to inhibit the post translational processing and release of interleukin-1β.

摘要翻译： 人α-防御素是过渡性处理和释放后白细胞介素-1β的抑制剂。 白介素-1beta是涉及炎性过程的引发和扩增的关键细胞因子，包括诸如克罗恩病和溃疡性结肠炎的疾病的炎症。 特别是主要由嗜中性粒细胞产生的人嗜中性粒细胞防御素-1（HNP-1），Paneth细胞产生的人α-防御素5（HD-5）已被发现阻断白细胞介素-1β后过渡处理和释放。 因此，本文公开了用于治疗哺乳动物组织中的炎症的药物组合物和方法。 药物组合物是治疗性补充代谢途径以减少炎症，其包含治疗有效量的人α-防御素或其酰胺，酯或其盐和药学上有效的载体。 用于治疗哺乳动物组织中的炎症的方法包括以有效抑制白细胞介素-1β的翻译后加工和释放的量向哺乳动物施用人α-防御素。

公开(公告)号：US08895062B2

公开(公告)日：2014-11-25

申请号：US12162011

申请日：2007-01-24

申请人： Erik P. H. De Leeuw ,  Wuyuan Lu

发明人： Erik P. H. De Leeuw ,  Wuyuan Lu

IPC分类号： A61K9/64 ,  A61K31/138 ,  A61K38/17 ,  A61K38/16 ,  A61K9/50 ,  A61K47/32 ,  A61K47/34

CPC分类号： A61K31/138 ,  A61K9/5052 ,  A61K9/5068 ,  A61K38/164 ,  A61K38/1729 ,  A61K47/32 ,  A61K47/34 ,  Y02A50/475 ,  Y02A50/481

摘要： The invention provides surface-layer protein coated microspheres for delivery of a therapeutic agent to the intestine. These surface-layer protein coated microspheres generally include a core encapsulated by a microsphere which is coated by surface layer protein. The core includes a therapeutic agent, such as a defensin. The invention also includes methods of making and using the surface-layer protein coated microspheres of the invention for administering therapeutic agents to a subject in need thereof. The invention also includes pharmaceutical dosage units that include the surface-layer protein coated microspheres of the invention. The invention further includes various labeled defensins for use in the study of the properties and actions of defensins, and further includes the use of defensins, particularly HD5α in the treatment of inflammatory conditions of the bowel, such as Crohn's disease.

摘要翻译： 本发明提供了用于将治疗剂递送至肠的表面层蛋白质包被的微球。 这些表面层蛋白质包被的微球通常包括由表面蛋白质包被的微球包裹的核心。 核心包括治疗剂，如防御素。 本发明还包括制备和使用本发明的表面层蛋白质包被的微球的方法，用于向有需要的受试者施用治疗剂。 本发明还包括药物剂量单位，其包括本发明的表面层蛋白质包被的微球。 本发明还包括用于研究防卫素的性质和作用的各种标记的防御素，并且还包括使用防御素，特别是HD5α用于治疗肠炎症性疾病如克罗恩病。